PMID- 32617013
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220415
IS  - 1178-7007 (Print)
IS  - 1178-7007 (Electronic)
IS  - 1178-7007 (Linking)
VI  - 13
DP  - 2020
TI  - Effects of MK-7 Supplementation on Glycemic Status, Anthropometric Indices and 
      Lipid Profile in Patients with Type 2 Diabetes: A Randomized Controlled Trial.
PG  - 2239-2249
LID - 10.2147/DMSO.S253014 [doi]
AB  - BACKGROUND: Type 2 diabetes mellitus (T2DM) is a prevalent disorder which 
      accounts for 90-95% of diabetic patients. The aim of this study was to assess the 
      effects of menaquinone (MK-7) supplementation on glycemic indices, anthropometric 
      indices and lipid profile, among patients with T2DM. METHODS: In this 
      double-blind placebo-controlled randomized clinical trial, 60 men and women with 
      T2DM were allocated equally into either the MK-7 (200 microg/day) or the placebo 
      group. Physical activity level and dietary intake were assessed using the 
      international physical activity questionnaire-short form (IPAQ-SF) and a 3-day 
      food record, pre- and post-intervention. Anthropometric measures, blood pressure, 
      glycemic indices and lipid profile including fasting blood sugar (FBS), 
      hemoglobin A1c (HBA1C), fasting insulin (FI), homeostatic model assessment 
      insulin resistance index (HOMA-IR), triglycerides (TG), total cholesterol (TC), 
      high-density lipoprotein (HDL-C) and low-density lipoprotein (LDL-C) were 
      measured at baseline and after twelve weeks. RESULTS: Forty-five patients 
      completed the trial. There were no significant between-group differences for 
      calorie intake, macronutrient intake, physical activity level or anthropometric 
      measures at baseline and at the end of the study. Dietary vitamin K intake 
      increased significantly at the end of the study in the MK-7 (p: 0.02) and placebo 
      (p: 0.001) groups, but intergroup differences were not significant (p: 0.86). FBS 
      (p: 0.01), HbA1c (p: 0.002), fasting insulin (p: 0.01) and HOMA-IR (p: 0.007) 
      decreased significantly in the MK-7 group. Furthermore, after adjustment for the 
      baseline values and changes of vitamin K intake at the end of study, FBS and 
      HbA1C showed significant intergroup changes, and they were significantly lower in 
      the MK-7 group compared to the placebo group. Lipid profile (TG, TC, LDL-C, HDL-C 
      and LDL-C/HDL-C) did not change significantly within or between groups. 
      CONCLUSION: MK-7 supplementation seems to be effective in the improvement of 
      glycemic indices, but not the lipid profile of patients with T2DM. CLINICAL TRIAL 
      REGISTRATION: The present study was prospectively registered at the Iranian 
      Registry of Clinical Trials on May 2019 (ID: IRCT20100123003140N22).
CI  - (c) 2020 Karamzad et al.
FAU - Karamzad, Nahid
AU  - Karamzad N
AUID- ORCID: 0000-0003-1628-1348
AD  - Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.
AD  - Department of Biochemistry and Diet Therapy, Faculty of Nutrition and Food 
      Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.
AD  - Nutrition Research Center, Faculty of Nutrition and Food Sciences, Tabriz 
      University of Medical Sciences, Tabriz, Iran.
FAU - Faraji, Esmaeil
AU  - Faraji E
AD  - Endocrine Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
FAU - Adeli, Shaghayegh
AU  - Adeli S
AD  - Department of Biochemistry and Diet Therapy, Faculty of Nutrition and Food 
      Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.
FAU - Carson-Chahhoud, Kristin
AU  - Carson-Chahhoud K
AD  - Australian Centre for Precision Health, School of Health Sciences, University of 
      South Australia, Adelaide, South Australia, Australia.
AD  - School of Medicine, University of Adelaide, Adelaide, South Australia, Australia.
FAU - Azizi, Samaneh
AU  - Azizi S
AUID- ORCID: 0000-0003-4577-9487
AD  - Department of Biochemistry and Diet Therapy, Faculty of Nutrition and Food 
      Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.
FAU - Pourghassem Gargari, Bahram
AU  - Pourghassem Gargari B
AUID- ORCID: 0000-0001-7667-099X
AD  - Department of Biochemistry and Diet Therapy, Faculty of Nutrition and Food 
      Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.
AD  - Nutrition Research Center, Faculty of Nutrition and Food Sciences, Tabriz 
      University of Medical Sciences, Tabriz, Iran.
LA  - eng
PT  - Journal Article
DEP - 20200626
PL  - New Zealand
TA  - Diabetes Metab Syndr Obes
JT  - Diabetes, metabolic syndrome and obesity : targets and therapy
JID - 101515585
PMC - PMC7326202
OTO - NOTNLM
OT  - MK-7
OT  - anthropometric indices
OT  - diabetes
OT  - dyslipidemia
OT  - glycemic status
OT  - menaquinone
OT  - phylloquinone
OT  - vitamin K
COIS- The authors declare no conflict of interest.
EDAT- 2020/07/04 06:00
MHDA- 2020/07/04 06:01
PMCR- 2020/06/26
CRDT- 2020/07/04 06:00
PHST- 2020/03/08 00:00 [received]
PHST- 2020/06/11 00:00 [accepted]
PHST- 2020/07/04 06:00 [entrez]
PHST- 2020/07/04 06:00 [pubmed]
PHST- 2020/07/04 06:01 [medline]
PHST- 2020/06/26 00:00 [pmc-release]
AID - 253014 [pii]
AID - 10.2147/DMSO.S253014 [doi]
PST - epublish
SO  - Diabetes Metab Syndr Obes. 2020 Jun 26;13:2239-2249. doi: 10.2147/DMSO.S253014. 
      eCollection 2020.